News Digest 13.05.2024 — 15.05.2024
Regulators
The government plans to clarify the codes of medical goods for the purposes of applying the VAT rate of 10%
The clarifications are related to changes in the OKPD 2 classifier.
Source: https://www.consultant.ru/law/hotdocs/84657.html
Deputies proposed mandatory labeling of alcohol-containing non-food products
Deputies introduced bill No. 623458-8 to the State Duma, which provides for mandatory identification labeling of alcohol-containing non-food products with an ethyl alcohol content of more than 10% of the volume of finished products in accordance with the list established by the government.
The document concerns organizations involved in the production and distribution of alcohol-containing non-food products, as well as individual entrepreneurs who purchase and retail such products. They are proposed to be required to provide information on the volume of production and turnover of products to the relevant state information system.
A ban is also established on the purchase (except for import) and supply (except for export) of alcohol-containing non-food products at prices lower than the corresponding purchase (supply) prices of alcoholic products. In addition, a restriction is established for separate divisions of organizations on combining activities for the production of alcohol-containing non-food products with activities for the production of alcoholic products.
The explanatory note to the document states that the reason for its development was that unscrupulous entrepreneurs take advantage of the “non-excise” status of certain alcohol-containing non-food products and purchase food-grade ethyl alcohol as a raw material without paying excise duty. The introduction of purchased food grade ethyl alcohol into illegal circulation endangers the lives and health of citizens and “causes significant damage to the budget system.”
If approved, the law will come into force from the date of its official publication, with the exception of some subparagraphs - they will come into force on July 1, 2025.
Market news
The range of nebulizers expanded in the first quarter due to Chinese companies
The Russian retail nebulizer market (including the e-com segment) reached RUB 1.8 billion in the first quarter of 2024. (at retail prices, including VAT). In total, almost 752 thousand units were sold during this period. relevant devices. Compared to the first quarter of last year, the market increased by 38% in monetary terms and by 51% in physical units, RNC Pharma analysts calculated.
For the entire 2023, 1.93 million units were sold. in the amount of 4.86 billion rubles. The dynamics relative to 2022 in rubles was lower - 0.5%, while natural consumption increased by almost 10%. The market is experiencing a serious change in the assortment and, as a result, a reduction in the average price of sold products. During the reporting period, one inhaler cost an average of 2.39 thousand rubles, while a year earlier it cost 2.61 thousand rubles. The nebulizer market, as well as almost all categories of consumer medical equipment, had a negative price index in 2023. In the first quarter of 2024, prices began to rise, and relative to the same period in 2023, inflation was 3.3%.
In the analyzed period, about 32% of the total sales volume of nebulizers came from the online channel. In physical terms, the share of the e-com direction is even larger - 45%, while a year ago this figure was only 33%. The pace of development of e-commerce exceeds the dynamics of the traditional channel - relative to the first quarter of 2023, online sales increased by 63% in rubles, and physical consumption doubled. Nevertheless, the offline channel also shows significant growth - in monetary terms the dynamics are +29%, in physical terms +25%.
Nebulizers from Japanese manufacturers are mainly represented on the Russian retail market; they account for more than 45% in this category. Nebulizers from Switzerland and Singapore take second and third places in terms of value - 24 and 14%, respectively. In the first three months of this year, there were 44 brands from 10 countries in retail, including a few domestic products. The latter accounts for only 0.2% of the market value.
During the reporting period, 39 companies presented their products to the market; sales of five of them were not recorded in the first quarter of 2023; some of them appeared on the market in the second half of 2023. The expansion of the range of nebulizers is mainly due to Chinese companies; for example, three new players in the first quarter of 2024 presented products from this country.
Among the new Chinese manufacturers is the Tolife corporation, which introduced the Ingalife compressor inhaler to the Russian market and took eighth place in the ranking of companies by monetary volume in the first quarter of 2024 with a share of just over 1%. Two other new players from China still have insignificant shares in our market - a total of 0.06%. The leader in the nebulizer segment remains the Japanese corporation Omron with a market share in rubles of 29%, the second place in the ranking is the Swiss B.Well (23%), and the Japanese A&D (16%) closes the top three.
The maximum dynamics in the TOP10 corporations was demonstrated by the Chinese companies Glenmark and Xiaomi Technology: sales of inhalers of these companies increased by 77 and 72%, respectively, in value terms. Among the top players, the Japanese A&D is noted - the company showed an increase in sales of almost 70%.
PIMU proposed a method for rapid diagnosis of early caries
Scientists from the Research Institute of Experimental Oncology and Biomedical Technologies of the Volga Research Medical University (PIMU) proposed diagnosing caries using a high-resolution optical coherence tomography (OCT) method, the press service of the medical university told MV. The device, developed at the Institute of Applied Physics of the Russian Academy of Sciences, makes it possible to distinguish the initial forms of caries from dental plaque by the attenuation coefficient of the OCT signal, as well as clearly determine the border of the carious lesion, which is impossible to do with other known methods.
At the very beginning, caries manifests itself weakly, which often leads to neglect of the pathological process and delayed treatment. Most often, dentists diagnose hard dental tissues using x-rays, but the degree of damage to the enamel and the severity of demineralization with this method are not always noticeable to the doctor. The disadvantages of radiography also include radiation exposure and the presence of contraindications.
PIMU believes that OCT will make it possible to quickly determine the stage of caries. Now this method is widely used in ophthalmology to evaluate the retina.
Source: https://medvestnik.ru/content/news/V-PIMU-predlojili-metod-ekspress-diagnostiki-rannego-kariesa.html
Novosibirsk Zdravmedtekh opened the production of medical clothing in Uzbekistan for 10 million rubles
The company "Zdravmedtekh-Novosibirsk" became part of the chemical-industrial park of the city of Chirchik, Tashkent region Uzbekistanаna in November 2023, a month later Zdravmedtech-Asia LLC was registered.
The grand opening of the enterprise took place at the end of April. According to the general director of Novosibirsk Zdravmedtekh Alexey Klevasov, 22 people will work at the plant. They will be trained for three months. Gradually, the company's staff is planned to increase to 100 people. As Klevasov noted, students from Uzbekistan studying at the Novosibirsk State Medical University will be able to become potential employees of the Zdravmedtech-Asia company.
Zdravmedtech-Asia will produce a line of medical products corresponding to those produced at the head plant in Berdsk. These are disposable medical clothing and linen (surgical gowns, caps, shoe covers), surgical sheets, napkins and medical masks.
Zdravmedtekh-Novosibirsk LLC has been operating in Berdsk since 2003, the company employs 320 people. The company includes two branches - in the cities of Chulym and Tatarsk, where 80 people work. The Zdravmedtech structure also includes the Zdravmedtech-Siberia trading house. The suppliers of raw materials for the production of products are 75% Russian enterprises, another 25% of raw materials come from China.
According to the general director of the company, in 2023 the revenue of Zdravmedtekh-Novosibirsk LLC amounted to 885 million rubles. In 2024, it is planned to increase revenue to 1.2 billion rubles. The company also intends to expand production in the Lugansk and Donetsk republics, Kherson and Zaporozhye regions.
According to SPARK-Interfax, Zdravmedtekh-Novosibirsk LLC is 58% owned by Alexey Klevasov, another 21% each by Denis and Evgeny Klevasov. Revenue, according to information from the system, in 2023 amounted to 621 million rubles, net profit - 41.5 million rubles.
In April 2024, the governor of the Voronezh region, Alexander Gusev, approved a project to create a plant for the production of medical Foley catheters in the Center SEZ. Representatives of the Caspis BioTech company came up with the idea of organizing production. Investments in the project were estimated at 285 million rubles. According to the company, full-cycle production will be the first in Russia and will allow the production of up to 5 million catheters per year.
Other
Noninvasive test developed to detect high-grade prostate cancer
Scientists from the University of Michigan and Vanderbilt University have developed a test that can detect an aggressive form of prostate cancer using a urine test. Data on its use are published on the website of the US National Institutes of Health (NIH).
To create the test, the results of RNA sequencing of 59 thousand genes were analyzed and 54 candidate markers associated with prostate cancer or low-grade cancer were identified. All of them were detected in urine. Further analysis and modeling involving 761 patients identified a combination of 17 genes that predicted high-grade cancer. In addition, the scientists added a gene associated with normal prostate tissue. The new 18-gene test is called MyProstateScore 2.0 (MPS2).
To validate the test, urine samples were used from an additional 743 people who underwent biopsies due to elevated PSA levels. Biopsy results revealed high-grade cancer in 20% of participants.
The analysis showed that the use of MPS2 can detect the presence of low-grade cancer with 97% accuracy. According to the authors, widespread use of the test will avoid up to 51% of unnecessary biopsies.
Among nearly 800 participants with elevated PSA levels, the new test was able to detect the presence of clinically significant prostate cancer with surprising accuracy, according to Jeffrey Tosoyan of Vanderbilt University. With MPS2, half of patients can avoid unpleasant and invasive procedures, including MRI and prostate biopsy, with complete confidence that nothing is missed.
Elon Musk's brain implant turned out to be of poor quality
Last week, right on Victory Day, Elon Musk’s company Neuralink, which implanted a brain implant in a man’s brain, reported a problem with this same implant - several contacts of the device that read neural signals were disconnected from the brain, writes Forbes.
As a result, the number of electrodes that monitor brain signals has decreased. However, the company’s message did not mention negative consequences for the patient’s health and did not specify how many of the device’s 64 wires failed.
The fact is that the company knew about the problem and deliberately kept silent about it, considering that the risk of a “bug” was minimal.
News
